Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising PEG moieties for stabilization of a cell

Patent metadata

Field	Value
Publication number	US-11021472-B2
Application number	US-201615186580-A
Country	US
Kind code	B2
Filing date	Jun 20, 2016
Priority date	Dec 20, 2013
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

The present invention relates to the use compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising a polyethylene glycol (PEG) moiety for stabilization of a cell, and methods related thereto.

First claim

The invention claimed is:

1. A method comprising:
providing a compound comprising two or more hydrophobic domains attached to a hydrophilic domain,
wherein the two or more hydrophobic domains are covalently bound to said hydrophilic domain, and wherein the two or more hydrophobic domains each comprise a linear lipid, cholesterol or a hydrophobic vitamin, and
wherein the hydrophilic domain comprises a polyethylene glycol (PEG) moiety, and

contacting said compound to a cell under in vitro conditions allowing the compound to incorporate into the membrane of the cell, wherein said contacting results in stabilization of the cell, wherein said compound comprises a compound of Formula (I):
X1-[A1-(L1) n ] k1 -Z-[A2-(L1) n ] k2 -X2  (I),

wherein Z is a linear polyethylene glycol (PEG) moiety containing 2 to 100 linear PEG moieties, wherein the linear PEG moiety optionally comprises 1 or more spacer moieties SP connecting two —O—CH 2 —CH 2 — moieties, and wherein the linear PEG moiety optionally comprises a linker moiety L3 at one or both ends,
each L1 is a linker moiety selected independently from each other,
each n is either 0 or 1, selected independently from each other,
A1 and A2 are bifunctional or trifunctional moieties selected independently from each other, and at least one A1 or A2 is trifunctional,
k1 and k2 are integers between 0 and 10, selected independently from each other, and at least one of k1 and k2 is not 0,
X1 and X2 are independently selected from hydrogen, a protecting group, and a hydrophobic group,
L3 is independently selected from a linear alkyl or alkenyl chain with 1 to 10 C atoms, which is optionally (i) interrupted by 1 to 3 N, O or S atoms, and/or (ii) substituted by 1 to 4 hydroxyl, carbonyl, amino or thiol groups, and
wherein the two or more hydrophobic domains are covalently bound to said hydrophilic domain via the trifunctional moieties, or a salt thereof.

2. The method of claim 1 , wherein Z in Formula (I) has the following structure:
-(L3) n2 -[[O—CH 2 —CH 2 ] y —(SP) n1 ] m —[O—CH 2 —CH 2 ] y1 -(L3) n2 ,

wherein SP is a spacer moiety,
n1 is either 0 or 1,
each n2 is either 0 or 1, selected independently of each other,
m is an integer from 1 to 100,
y is an integer from 1 to 100,
y1 is an integer from 0 to 30,
with the proviso that y*m+y1≤100,
L3 is independently selected from a linear alkyl chain with 1 to 10 C atoms and a linear alkenyl chain with 2 to 10 C atoms, wherein said linear alkyl chain or linear alkenyl chain is optionally (i) interrupted by 1 to 3 N, O or S atoms, and/or (ii) substituted by 1 to 4 hydroxyl, carbonyl, or thiol groups.

3. The method of claim 2 , wherein
(a) n1 is identical for the m moieties —[[O—CH 2 —CH 2 ] y —(SP) n1 ]—, and/or
(b) y1 is 0, and/or
(c) y is 4, 5, or 6, and n1 is 1, and/or
(d) the spacer moieties SP are independently from each other selected from the group consisting of a phosphate, and a bifunctional moiety, and/or
(e) n2 is both 0, or
(f) one or both n2=1, and L3 is an alkyl group with 1 to 10 C atoms which optionally contains an amide group, carbonyl group, carbamate, and/or NH group.

4. The method of claim 1 , wherein X1 or X2 is a hydrophobic domain.

5. The method of claim 4 , wherein the linear lipid is (a) a saturated or unsaturated fatty acid, and/or (b) a fatty acid having from 8 to 26 C atoms, or the linear lipid is selected from the group consisting of oleic acid, myristic acid, stearic acid and behenic acid.

6. The method of claim 1 , wherein the hydrophobic vitamin is α-tocopherol.

7. The method of claim 1 , wherein
(a) the linkers L1 are independently selected from the group consisting of a phosphate, amide, carbamate, and ester group, and/or
(b) moieties A1 and A2 are independently selected from
a bifunctional group selected from the group consisting of a phosphate group, carbamate group, amide group, a moiety comprising a nucleobase, and a linear alkyl group having 1 to 10 C atoms and which alkyl chain contains functional groups at the terminal C-atoms independently selected from amine, carbonyl, hydroxyl, thiol, and carbonic acid groups, and
a trifunctional moiety having 1 to 10 C atoms and comprising at least one —OH, —SH and/or at least one —NH 2 group, and/or
(c) the linkers L2 are independently selected from the group consisting of a phosphate, amide, carbamate, an ester group and a moiety —[[O—CH 2 —CH 2 ] y2 —(SP) n ] m1 —, wherein SP and n are as in claim 3 , y2 is an integer from 1 to 30, and m1 is an integer from 1 to 10.

8. A method of stabilizing a cell during exposure to shear forces, the method comprising
(a) providing a compound as defined in claim 1 ; and
(b) contacting a cell with the compound under conditions allowing the interaction of the compound with the membrane of the cell wherein the compound incorporates into the membrane of the cell, thereby stabilizing the cell, and
(c) applying shear forces to the cell.

9. The method of claim 8 , wherein the applying shear forces to the cell is by centrifugation, large scale cell cultivation, flow cytometry, fluorescence-activated cell sorting and/or bead-based cell separation.

Assignees

• Roche Diagnostics Operations Inc

Inventors

• Josel Hans-Peter
• Heindl Dieter
• Froehlich Thomas
• Froehner Stefanie

Classifications

• C12N2533/20

  Small organic molecules · CPC title

• C07D409/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• G01N33/54353

  with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393) · CPC title

• C07J51/00

  Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00 · CPC title

• G01N33/5005

  involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025) · CPC title